Citadel has taken a short position worth 305 million pounds ($384.5 million) in GSK stock, representing a 0.51% stake, according to data from the Financial Conduct Authority, the FT report said.

Hedge fund Citadel has made a £305mn bet against drugmaker GSK, the biggest short position against the company in more than a decade.

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/106.Ckjk1Vbt.js ...

Single-family homes priced below $500,000 are getting harder to come by, as wealthy buyers drive up demand for high-end homes ...

The Carnegie Museum of Natural History in Pittsburgh, home to the Tyrannosaurus rex holotype and a famous Diplodocus, will ...

Ken Griffin, founder of investment firm Citadel, warned Tuesday that President Donald Trump's tariff policies pose a serious ...

Citadel CEO Ken Griffin had some strong words about the harmful effects of U.S. President Donald Trump's tariffs. Read more here.

Live Updates S&P 500's Worst Performer and Tariff 'Chaos' 1:38 pm As of mid-afternoon, the Dow Jones Industrial Average and S ...

This $200 million lot on Palm Beach's Billionaire's Row lets you build your dream home with both oceanfront and intracoastal ...

A Bloomberg analysis of the major hedge funds’ regulatory filings shows their passthrough fees have exploded in recent years.